Evommune, Inc., a clinical-stage biotechnology company discovering and developing new ways to treat inflammatory diseases, today announced the completion of a $50 million Series B financing.
Endo International plc (OTC: ENDPQ) announced today that its subsidiaries Endo Ventures Limited and Par Pharmaceutical, Inc. (collectively “Endo”) have executed an agreement with Slayback Pharma LLC to distribute Slayback’s Prevduo ™ (neostigmine methylsulfate and glycopyrrolate injection) pre-filled syringe on an exclusive basis in the U.S.
Alloy Therapeutics, a biotechnology ecosystem company, announced the appointment of Kent Bondensgaard and John “Lippy” Lippincott as the latest members of its team, joining as Senior Vice President of Antibody Discovery Services and Senior Vice President of Therapeutic Discovery Strategies, respectively.
Xencor, Inc. today announced the appointment of Nancy Valente, M.D., to Executive Vice President, Chief Development Officer.
Xencor Appoints Nancy Valente, M.D., as Chief Development Officer Read More »
En este Short conoceremos los dos tipos de colesterol y los posibles efectos perniciosos de uno de ellos. …
Stallergenes Greer, a biopharmaceutical company specialising in the research, diagnosis and treatment of respiratory allergies, is pleased to announce its strategic direction for the Stallergenes Greer Foundation.
LinKinVax, a clinical-stage biotechnology company, announces the creation of its Scientific Advisory Board with the appointment of three experts in immunology and epidemiology.
Surmodics, Inc. today reported financial results for its second quarter ended March 31, 2023, and updated its financial guidance for its fiscal year ending September 30, 2023.
Thermo Fisher Scientific Inc., the world leader in serving science, reported its financial results for the first quarter ended April 1, 2023.
Thermo Fisher Scientific Reports First Quarter 2023 Results Read More »
Orbital Therapeutics, a company focused on enhancing global health by unleashing the full potential of RNA medicines to treat human disease, announced the successful closing of $270 million Series A financing.
